«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:

36

期数:

2019年7

页码:

665-669

栏目:

临床研究

出版日期:

2019-07-05

文章信息/Info

Title:

Effect and safety of menatetrenone capsule combined with salmon calcitonin in the treatment of senile osteoporosis

作者:

许环顺¹; 侯　平¹; 邢　忠¹; 王　斌¹; 周　钢²

（1.海口市第三人民医院骨科，海南　海口　571100；2.海南省人民医院关节外科，海南　海口　570311）

Author(s):

XU Huan-shun¹; HOU Ping¹; XING Zhong¹; WANG Bin¹; ZHOU Gang²

(1.Department of Orthopedics,the Third People′s Hospital of Haikou City,Haikou 571100,Hainan Province,China;2.Department of Joint Surgery,Hainan Provincial People′s Hospital,Haikou 570311,Hainan Province,China)

关键词:

四烯甲萘醌胶囊; 鲑鱼降钙素; 老年性骨质疏松症

Keywords:

menatetrenone capsule; salmon calcitonin; senile osteoporosis

分类号:

R681

DOI:

10.7683/xxyxyxb.2019.07.016

文献标志码:

A

摘要:

目的　探讨四烯甲萘醌胶囊联合鲑鱼降钙素治疗老年性骨质疏松症疗效及安全性。方法　选择2016年7月至2017年7月海口市第三人民医院收治的86例老年性骨质疏松症患者为研究对象，根据治疗方法分为观察组和对照组，每组43例，对照组患者给予鲑鱼降钙素治疗，观察组患者给予四烯甲萘醌胶囊联合鲑鱼降钙素治疗，2组患者均治疗12周。2组患者分别于治疗前、治疗4、12周后采用视觉模拟评分法（VAS）进行疼痛评分；分别于治疗前、治疗12周后使用双能X线骨密度测定仪检测腰椎骨密度，采用放射免疫法检测血清骨钙素（BGP）和降钙素（CT）水平，应用全自动生物化学分析仪检测血清甲状旁腺激素（PTH）和血清碱性磷酸酶（ALP）水平及尿钙、肌酐水平，并计算尿钙/肌酐比值；治疗期间观察2组患者不良反应发生情况。结果　治疗前2组患者VAS评分比较差异无统计学意义（P>0.05）；2组患者治疗4、12周后VAS评分显著低于治疗前（P<0.05），治疗12周后VAS评分显著低于治疗4周（P<0.05）；治疗4、12周后，观察组患者VAS评分显著低于对照组（P<0.05）。治疗前2组患者腰椎骨密度比较差异无统计学意义（P>0.05），2组患者治疗12周后腰椎骨密度显著大于治疗前（P<0.05）；治疗12周后，观察组患者腰椎骨密度大于对照组（P<0.05）。治疗前2组患者血清BGP和CT水平比较差异无统计学意义（P>0.05），2组患者治疗12周后血清BGP和CT水平显著高于治疗前（P<0.05）；治疗12周后，观察组患者BGP和CT水平显著高于对照组（P<0.05）。治疗前2组患者血清PTH、ALP水平及尿钙/肌酐比值比较差异无统计学意义（P>0.05）；对照组患者治疗12周后血清PTH水平显著低于治疗前（P<0.05），对照组患者治疗前后血清ALP水平及尿钙/肌酐比值比较差异无统计学意义（P>0.05）；观察组患者治疗12周后血清PTH、ALP及尿钙/肌酐水平显著低于治疗前（P<0.05）；治疗12周后，观察组患者血清PTH、ALP水平及尿钙/肌酐比值显著低于对照组（P<0.05）。观察组和对照组患者不良反应发生率分别为11.63%（5/43）、18.60%（8/43），2组患者不良反应发生率比较差异无统计学意义（χ²=1.549，P>0.05）。结论　四烯甲萘醌胶囊联合鲑鱼降钙素治疗老年性骨质疏松症的临床疗效确切，且安全性好，可显著缓解患者疼痛，促进新骨形成，提高患者骨密度。

Abstract:

Objective　To investigate the effect and safety of menatetrenone capsule combined with salmon calcitonin in the treatment of senile osteoporosis.Methods　A total of 86 patients with senile osteoporosis admitted to the Third People′s Hospital of Haikou City from July 2016 to July 2017 were selected as subjects,and they were divided into observation group and control group according to the treatment method,43 cases in each group.The patients in the control group were treated with salmon calcitonin,while the patients in the observation group were treated with menatetrenone capsule and salmon calcitonin,all patients were treated for 12 weeks.The pain of patients in the two groups was evaluated by visual analogue scale (VAS) at the time points of before treatment,4 and 12 weeks after treatment.Before treatment and 12 weeks after treatment,the bone density of lumbar spine was measured by dual energy X-ray absorptiometry,the levels of serum osteocalcin (BGP) and calcitonin (CT) were detected by radioimmunoassay,the levels of serum parathyroid hormone (PTH)，alkaline phosphatase (ALP),the levels of urine calcium and creatinine were detected by automatic biochemical analyzer,and the ratio of urinary calcium to creatinine was calculated.The adverse reactions of patients in the two groups were observed during the treatment.Results　There was no significant difference in VAS score between the two groups before treatment (P>0.05).The VAS score of patients after 4 and 12 weeks of treatment was significantly lower than that before treatment in the two groups(P<0.05),and the VAS score after 12 weeks of treatment was significantly lower than that after 4 weeks of treatment (P<0.05).After 4 and 12 weeks of treatment,the VAS score of patients in the observation group was significantly lower than that in the control group (P<0.05).There was no significant difference in bone density of lumbar spine between the two groups before treatment (P>0.05).The bone density of lumbar spine after 12 weeks of treatment was significantly greater than that before treatment in the two groups (P<0.05).The bone density of lumbar spine in the observation group was greater than that in the control group after 12 weeks of treatment (P<0.05).There was no significant difference in the levels of serum BGP and CT between the two groups before treatment (P>0.05).The levels of serum BGP and CT after 12 weeks of treatment were significantly higher than those before treatment in the two groups (P<0.05).The levels of serum BGP and CT in the observation group were significantly higher than those in the control group after 12 weeks of treatment (P<0.05).There was no significant difference in serum PTH and ALP levels and the ratio of urinary calcium to creatinine between the two groups before treatment (P>0.05).The level of serum PTH after 12 weeks of treatment was significantly lower than that before treatment in the control group (P<0.05).There was no significant difference in serum ALP level and the ratio of urinary calcium to creatinine before and after 12 weeks of treatment in the control group (P>0.05).The levels of serum PTH,ALP and the ratio of urinary calcium to creatinine after 12 weeks of treatment were significantly lower than those before treatment in the observation group (P<0.05).After 12 weeks of treatment,the levels of serum PTH,ALP and the ratio of urinary calcium to creatinine in the observation group were significantly lower than those in the control group (P<0.05).The incidence of adverse reactions in the observation group and the control group was 11.63% (5/43) and 18.60% (8/43),respectively.There was no significant difference in the incidence of adverse reactions between the two groups (χ²=1.549,P>0.05).Conclusion　Menatetrenone capsule combined with salmon calcitonin has definite clinical efficacy and good safety in the treatment of senile osteoporosis.It can significantly alleviate pain,promote new bone formation,and improve bone density.

常用功能

更新日期/Last Update: 2019-07-05